Drug
Bevacizumab-IRDye 800CW clinical trials
Also written Beva-800CW.
- studies test it
- 17
- open now
- 1
- in phase 3
- 0
- first study started
- 2011
Keep track of what changes. Save the Bevacizumab-IRDye 800CW studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 17
University Medical Center Groningen (16) · Technical University of Munich (1)
Studies
Open first, then newest update. How each study uses Bevacizumab-IRDye 800CW is read from its arms, and is right about nine times in ten.
Testing it · 17
- Safety and Feasibility of Immuno-OCTNot yet recruitingNot applicableUniversity Medical Center GroningenNCT06008522Written as Bevacizumab-800CW
- Targeted Fluorescence Imaging in AMDCompletedPhase 1University Medical Center GroningenNCT05262244Written as Bevacizumab-IRDye800CW
- Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CWCompletedPhase 1University Medical Center GroningenNCT06095362Written as Bevacizumab-IRDye800CW
- Visualization of Rectal Cancer During Endoscopy, Using a Fluorescent TracerCompletedPhase 1University Medical Center GroningenNCT01972373Written as Bevacizumab-IRDye800CW
- VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal LesionsCompletedPhase 1University Medical Center GroningenNCT02129933Written as Bevacizumab-IRDye800CW
- Fluorescence Endoscopy of Esophageal CarcinomaTerminatedPhase 1University Medical Center GroningenNCT03558724Written as Bevacizumab-IRDye800CW
- Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CWCompletedPhase 1University Medical Center GroningenNCT02113202Written as Bevacizumab-IRDye800CW
- Detection of PitNET Tissue During TSS Using Bevacizumab-800CWCompletedPhase 1University Medical Center GroningenNCT04212793Written as Bevacizumab-IRDye800CW
- Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CWWithdrawnPhase 2Technical University of MunichNCT05359874Written as Bevacizumab-IRDye800CW
- Image Guided Surgery in Sinonasal Inverted PapillomaStatus unknownPhase 1University Medical Center GroningenNCT03925285Written as Bevacizumab-800CW
- Fluorescence Image Guided Surgery in CholangiocarcinomaStatus unknownPhase 1/2University Medical Center GroningenNCT03620292Written as Bevacizumab-IRDye800CW
- Detection of Early Esophageal Cancer by NIR-FME.Status unknownPhase 2University Medical Center GroningenNCT03877601Written as Bevacizumab-IRDye800CW
- FLuoresence Image Guided Surgery With A VEGF-targeted Tracer in Soft-tissue Sarcomas in Humans Approach With Bevacizumab-IRDye 800CWCompletedPhase 1/2University Medical Center GroningenNCT03913806Written as Bevacizumab-IRDye800CW
- Near-infrared Image Guided Surgery in Pancreatic AdenocarcinomaTerminatedPhase 1/2University Medical Center GroningenNCT02743975Written as Bevacizumab-800CW
- VEGF-targeted Fluorescent Tracer Imaging in Breast CancerCompletedPhase 1University Medical Center GroningenNCT01508572Written as bevacizumab-IRDye800CW
- Feasibility Study of Using Molecular Fluorescence Guided Surgery in EndometriosisStatus unknownPhase 1University Medical Center GroningenNCT02975219Written as Bevacizumab-800CW
- Fluorescence Guided Surgery in Breast CancerCompletedPhase 1/2University Medical Center GroningenNCT02583568Written as Bevacizumab-800CW